Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients
Status:
Terminated
Trial end date:
2018-09-28
Target enrollment:
Participant gender:
Summary
This research study studies the combination of ibrutinib and obinutuzumab with or without the
standard chemotherapy regimen of CHOP to see how well these drugs work in treating patients
with a diagnosis of Richter's Transformation or Richter's Syndrome. The Bruton's Tyrosine
Kinase (BTK) inhibitor, ibrutinib, may stop growth of cancer cells by blocking the signal
needed for cell growth. The monoclonal antibody obinutuzumab may block cancer growth by
targeting cells present in Richter's Transformation. Giving ibrutinib with obinutuzumab may
be a better treatment for patients with Richter's Transformation. Depending on fitness, the
patients may receive ibrutinib and obinutuzumab in combination with a regimen known as CHOP
(C= cyclophosphamide, H= hydroxydaunorubicin (also called doxorubicin), O= oncovin (also
called vincristine, and P= prednisolone or prednisone (corticosteroids).